Davis, M. R., Daggett, J. J., Pascual, A. S., Lam, J. M., Leyva, K. J., Cooper, K. E., & Hull, E. E. (2016). Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition. BMC Cancer.

Davis, McKale R., Juliane J. Daggett, Agnes S. Pascual, Jessica M. Lam, Kathryn J. Leyva, Kimbal E. Cooper, and Elizabeth E. Hull. "Epigenetically Maintained SW13+ and SW13- Subtypes Have Different Oncogenic Potential and Convert With HDAC1 Inhibition." BMC Cancer 2016.

Davis, McKale R., et al. "Epigenetically Maintained SW13+ and SW13- Subtypes Have Different Oncogenic Potential and Convert With HDAC1 Inhibition." BMC Cancer 2016.